Chemomab Therapeutics Ltd.

Chemomab Therapeutics (CMMB) shows no cyber incidents or red-flag 8-K filings in the past 90 days, suggesting operational stability in the near term. However, absence of recent events does not indicate absence of risk; our 90-day window captures only recent activity, while earlier filing patterns, equity dilution trends, and financing history may reveal longer-term vulnerabilities. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scores, contextualizes all 8-K events, and maps AI-flagged risk signals across the company's capital structure and cash position. This deeper lens transforms a clean recent record into a comprehensive risk assessment.